多肽CRDMO平台
目录肽
大奖888生化目录肽版块全新呈现，致力于打造全球最全面的多肽供应平台！我们专业的学术团队将时刻追踪最新最热的研究动向，帮助您发现实际需求，并以最高质量标准提供您所需要的产品。我们将我们将不定期更新产品列表，为您最大限度地节约科研时间，敬请广大客户朋友关注！
OSTP-008A
Osteostatin (human)\n
H-Thr-Arg-Ser-Ala-Trp-Leu-Asp-Ser-Gly-Val-Thr-Gly-Ser-Gly-Leu-Glu-Gly-Asp-His-Leu-Ser-Asp-Thr-Ser-Thr-Thr-Ser-Leu-Glu-Leu-Asp-Ser-Arg-OH\nTrifluoroacetate salt
H-Thr-Arg-Ser-Ala-Trp-Leu-Asp-Ser-Gly-Val-Thr-Gly-Ser-Gly-Leu-Glu-Gly-Asp-His-Leu-Ser-Asp-Thr-Ser-Thr-Thr-Ser-Leu-Glu-Leu-Asp-Ser-Arg-OH\nTrifluoroacetate salt
Size：0.5
P1(RMB)：1000
MW：3451.62
One letter sequence：TRSAWLDSGVTGSGLEGDHLSDTSTTSLELDSR
Molecular Formula：C142H228N42O58
Description：This peptide is the carboxyl-terminal fragment of pTHrP, which is a potent inhibitor of osteoclastic bone resorption. It is suggested that this product acts directly on osteoclasts.
Literature Reference：A.J.Fenton et al., Endocrinology, 129, 1762 (1991)\nA.J.Fenton et al., Endocrinology, 129, 3424 (1991)
Cas：137348-10-8
P1(RMB)：1000
MW：3451.62
One letter sequence：TRSAWLDSGVTGSGLEGDHLSDTSTTSLELDSR
Molecular Formula：C142H228N42O58
Description：This peptide is the carboxyl-terminal fragment of pTHrP, which is a potent inhibitor of osteoclastic bone resorption. It is suggested that this product acts directly on osteoclasts.
Literature Reference：A.J.Fenton et al., Endocrinology, 129, 1762 (1991)\nA.J.Fenton et al., Endocrinology, 129, 3424 (1991)
Cas：137348-10-8
